Streetbeat News

NVNO

enVVeno Medical Corporation

https://www.envveno.com

Industry

Medical - Devices

enVVeno Medical Corporation, a medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of severe deep venous chronic venous insufficiency. Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

enVVeno Medical announced it will present topline efficacy data from its VenoValve trial at the 2024 American Venous Forum Annual Meeting on March 6. This event is significant for investors as it could influence the company's stock performance based on the trial results.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 1:37 pm

enVVeno Medical Corporation (NASDAQ:NVNO) reported Q3 2023 financial results, ending the quarter with $25.7M in cash and investments. The company achieved full enrollment for its VenoValve U.S. pivotal trial and plans to expedite the development of enVVe, a transcatheter replacement venous valve. The company's cash burn for the quarter was $4.1M, in line with previous guidance. The company also closed a $28M private placement, which is expected to fund the company through several significant milestones.

Portfolio Pulse from Benzinga Newsdesk

October 26, 2023 | 12:24 pm

enVVeno Medical announced a private placement of $28 million, causing its shares to trade lower.

Portfolio Pulse from Bill Haddad

October 06, 2023 | 3:14 pm

enVVeno Medical Corporation (NASDAQ:NVNO) has announced a private placement of $28 million, conducted as an at-the-market offering under Nasdaq rules. The transaction was led by Perceptive Advisors, Nantahala Capital, Kingdon Capital Management, Velan Capital, L1 Capital and other institutional investors. The company could receive up to an additional $75 million from milestone-driven warrants upon the release of initial topline efficacy data from the VenoValve pivotal trial and FDA pre-market approval of the VenoValve.

Portfolio Pulse from Benzinga Newsdesk

October 06, 2023 | 12:58 pm

Envveno Medical has filed for a mixed shelf offering of up to $75 million.

Portfolio Pulse from Charles Gross

July 31, 2023 | 9:51 pm

enVVeno Medical has reported its Q2 2023 financial results, ending the quarter with $29.8 million in cash and investments.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2023 | 9:14 pm

During Wednesday's intraday session, several healthcare stocks experienced significant movements. Gainers included enVVeno Medical (NVNO), 60 Degrees (SXTP), Harrow Health (HROW), Panbela Therapeutics (PBLA), DermTech (DMTK), and bluebird bio (BLUE). Losers included Amarin Corp (AMRN), Aptevo Therapeutics (APVO), ViewRay (VRAY), Genprex (GNPX), 9 Meters Biopharma (NMTR), and Context Therapeutics (CNTX).

Portfolio Pulse from Benzinga Insights

July 19, 2023 | 5:31 pm

enVVeno Medical Corporation (NASDAQ:NVNO) has provided an update on its ongoing SAVVE U.S. pivotal study for the VenoValve, announcing that 57 patients have been enrolled so far, with full enrollment expected by the end of 2023. The company also announced two upcoming investor events. With $34.2 million in cash and investments, and a burn rate of between $4 million and $5 million per quarter, the company has sufficient resources to fund its current operations past the release of topline safety and efficacy data from the SAVVE study and through the end of 2024.

Portfolio Pulse from Happy Mohamed

July 05, 2023 | 12:22 pm

On Wednesday, 129 stocks hit new 52-week lows, with Qualcomm being the largest company by market cap to set a new low. QualTek Services' stock fell the most, down 38.7%, while Delaware Investments saw the sharpest rebound, with shares ascending 0.02%.

Portfolio Pulse from Benzinga Insights

May 24, 2023 | 4:49 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.